Ascendia

  MARKET NEWS

 

Valo Therapeutics & Texcell Announce Research Collaboration to Evaluate Immune Responses to PeptiCRAd-1 in Phase 1 Clinical Study
Salipro Biotech Expands Global Intellectual Property Portfolio With Granted Patent in Japan
Mustang Bio Announces Updated Results From Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
ABVC BioPharma ADHD Phase 2 Part 2 Clinical Study First Subject Enrolled at UCSF

  FEATURED EDITORIAL

  COMPANY PROFILE

As a top five CDMO, Recipharm delivers exceptional quality services and products through the entire drug/device combination development and manufacturing journey. We are at the forefront of drug delivery device innovation, thanks to the heritage of Bespak by Recipharm, which has over 60 years’ experience. We partner with pharma and biotech companies to deliver life-changing medicines, by providing design, development, and manufacture capabilities of innovative drug delivery devices. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Stevanato Group Presents Versatile On-Body Delivery System Platform for a Wide Range of Injectable Therapies & for Large Delivery Volumes

Stevanato Group Presents Versatile On-Body Delivery System Platform for a Wide Range of Injectable Therapies & for Large Delivery Volumes

The company offers the platform as a readily customizable pre-filled and pre-loaded on-body solution for drug delivery. Device development is making significant progress, with samples expected to be available in 2023…..

Quell Therapeutics Signs Collaboration, Exclusive Option & License Agreement With AstraZeneca to Develop, Manufacture & Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases

Quell Therapeutics Signs Collaboration, Exclusive Option & License Agreement With AstraZeneca to Develop, Manufacture & Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases

Collaboration brings together Quell’s proprietary multi-modular T-regulatory (Treg) cell engineering and manufacturing expertise with AstraZeneca’s proven development and commercial capabilities as well as its deep therapeutic area knowledge….

Axol Bioscience Collaborates With StrataStem to Deliver Stem Cell-Based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

Axol Bioscience Collaborates With StrataStem to Deliver Stem Cell-Based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

Axol Bioscience Ltd. has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples…..

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

The effectiveness of inhalation devices relies on their ability to deliver the pharmaceutical directly to the targeted part of the body with precision and calculated dosing.  Since these devices….

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Enhancing the Solubility of Active Pharmaceutical Ingredients Using Hot Melt Extrusion & Polyvinyl Alcohol

WHITEPAPER - Enhancing the Solubility of Active Pharmaceutical Ingredients Using Hot Melt Extrusion & Polyvinyl Alcohol

 

Solubility of the active pharmaceutical ingredient (API) in an oral formulation is critical for absorption from the gastrointestinal (GI) tract and the intended therapeutic effect. Ensuring that an API has the necessary solubility can be challenging for drug developers …

APPLICATION NOTE: Process Optimization & Preclinical Production Using the ANP System

APPLICATION NOTE: Process Optimization & Preclinical Production Using the ANP System

Particle Works is thrilled to announce the launch of a new Application Note that delves into the advancement of nanoparticles as carriers for targeted drug delivery. Developing nanoparticles for this purpose can be intricate and demanding, necessitating consistent, cost-effective, and …

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials

A key focus of the U.S. Food and Drug Administration’s evaluation of a medical device’s safety and effectiveness is reviewing its material makeup. If improperly tested – and impure materials are used – there is an elevated risk of contamination …

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

Aseptic processing with the highest degree of sterility assurance, filling accuracy, and quality is critical for high-value, small-batch therapies. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing.

CLICK HERE TO DOWNLOAD/VIEW THE …

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

 

Synchronizing and controlling API delivery, Extrusion-Spheronization (E-S) offers pharmaceutical drug developers a robust technique to develop and manufacture today’s most complex oral sold dose therapeutics.

Manufacturing oral solid dose API’s into spheres via Extrusion-Spheronization is not new. What is …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 21 – Bioavailability
June 28 – Excipients